drugset / Trial / NCT02262546

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

NCT02262546

Phase 1 Completed 60 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of the study is to assess that pramipexole does not prolong the QT interval more than placebo

Timeline

Start
2007-05
Primary completion
2007-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule
Subject Pramipexole Unknown 4.5 mg

Indications

No indication recorded.